In the year of Gen Suisse’s 25th anniversary, CEO Daniela Suter talks supporting dialogue between scientists and politicians on life sciences in Switzerland, educating the general population, the attractiveness of the Swiss community for scientists, and her goals for the future.
Could you give our international viewers an overview of Gen Suisse and its 25th anniversary?
The reputation of [Swiss] universities is also high, and in general [Switzerland] is a very attractive place to be.
Luye Pharma is a China-headquartered fully integrated oncology and CNS specialist. Bruno Delie, general manager for Switzerland, discusses the organization’s ambitious European expansion plan, looking to establish affiliates in the…
Karin Blumer, director of global patient engagement at Swiss giant Novartis, gives fascinating insights into the global patient advocacy landscape today and how Novartis interacts with it, the work being…
Barbara Fritsche-Surchat outlines Servier’s historic commitment to Switzerland, how the French mid-cap’s global oncology pivot is translating into its Swiss operations, and comments on the evolution of pharma salesforces post-pandemic.…
The DKK 56bn (EUR 7.5bn) Danish medtech industry employs 15,200 workers, accounts for 7.4 percent of Danish business and industry’s total research investments, contributes to 1.4 percent of national GDP,…
Denmark has long been at the vanguard of digitalisation, most notably in the form of comprehensive national health registries. This well-established footprint gave the Nordic nation a headstart in battling…
Walt Vernon is CEO of US-based healthcare facilities consulting firm, Mazzetti, and non-profit, Sextant. He is on the Board of the FGI and served on NFPA 99 ELS, NFPA 70…
See our Cookie Privacy Policy Here